258 related articles for article (PubMed ID: 17853922)
1. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
[TBL] [Abstract][Full Text] [Related]
3. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
[TBL] [Abstract][Full Text] [Related]
4. The role of ICP4 repressor activity in temporal expression of the IE-3 and latency-associated transcript promoters during HSV-1 infection.
Rivera-Gonzalez R; Imbalzano AN; Gu B; Deluca NA
Virology; 1994 Aug; 202(2):550-64. PubMed ID: 8030221
[TBL] [Abstract][Full Text] [Related]
5. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Lee CY; Bu LX; Rennie PS; Jia WW
Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
7. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
8. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells.
Katsura T; Iwai S; Ota Y; Shimizu H; Ikuta K; Yura Y
Cancer Gene Ther; 2009 Mar; 16(3):237-45. PubMed ID: 18949013
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
11. Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.
Longo SL; Griffith C; Glass A; Shillitoe EJ; Post DE
Cancer Gene Ther; 2011 Feb; 18(2):123-34. PubMed ID: 20930860
[TBL] [Abstract][Full Text] [Related]
12. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
14. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
15. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
18. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.
Ogawa F; Takaoka H; Iwai S; Aota K; Yura Y
Anticancer Res; 2008; 28(6A):3637-45. PubMed ID: 19189645
[TBL] [Abstract][Full Text] [Related]
19. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
20. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
